Heilmann Romy M, Grellet Aurélien, Allenspach Karin, Lecoindre Patrick, Day Michael J, Priestnall Simon L, Toresson Linda, Procoli Fabio, Grützner Niels, Suchodolski Jan S, Steiner Jörg M
Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, USA.
Royal Canin, Aimargues, France.
Vet Immunol Immunopathol. 2014 Apr 15;158(3-4):156-66. doi: 10.1016/j.vetimm.2014.01.006. Epub 2014 Jan 25.
Idiopathic inflammatory bowel disease (IBD) in dogs can be challenging to diagnose and fecal markers of disease that correlate with its severity could potentially be clinically useful. Surrogate inflammatory markers, such as the concentration of fecal S100A12, are used to detect active IBD in humans. The aim of this study was to determine the relationship between fecal canine S100A12 concentrations and clinical, endoscopic, and histologic disease severity. Twenty-six dogs with IBD and 90 healthy control dogs were enrolled. Spot fecal samples were collected and fecal canine S100A12 concentrations measured by an in-house ELISA. The correlation of fecal canine S100A12 concentrations with clinical disease activity (using the canine chronic enteropathy clinical activity index scoring system) and with endoscopic and histologic disease severity (using semi-quantitative grading systems) was assessed in dogs with IBD. Concentrations of fecal canine S100A12 were significantly higher in dogs with IBD (median [interquartile range]: 223 [21-3477]ng/g) than in healthy controls (median [interquartile range]: 9 [5-31]ng/g; P<0.0001). Fecal canine S100A12 concentrations correlated with the CCECAI score (ρ=0.4778; P=0.0408) and the severity of endoscopic lesions in the duodenum (ρ=0.4703; P=0.0354) and colon (ρ=0.9747; P=0.0144), but not with the severity of histopathologic changes except for inflammatory lesions in the colon (ρ=0.8669; P=0.0230). A concentration of 273ng fecal canine S100A12/g feces or greater distinguished (a) dogs with moderate to severe endoscopic disease in any GI section from dogs with at most mild endoscopic disease, and (b) dogs with very severe clinical disease (i.e., a CCECAI score of ≥12) from dogs with a CCECAI score of <12, with a sensitivity of 71% and 90%, respectively, and a specificity of 89% and 75%, respectively. This study showed that fecal canine S100A12 concentrations are increased in dogs with IBD. Further, this study showed that fecal canine S100A12 is associated with the clinical disease activity, the severity of endoscopic lesions, and the severity of colonic inflammation in dogs with IBD. Fecal S100A12 concentrations are potentially useful as a biomarker of inflammation in dogs with IBD.
犬特发性炎症性肠病（IBD）的诊断具有挑战性，与疾病严重程度相关的粪便标志物可能具有临床实用价值。替代炎症标志物，如粪便S100A12的浓度，被用于检测人类的活动性IBD。本研究的目的是确定犬粪便S100A12浓度与临床、内镜及组织学疾病严重程度之间的关系。纳入了26只患有IBD的犬和90只健康对照犬。采集即时粪便样本，采用内部酶联免疫吸附测定法（ELISA）测量犬粪便S100A12浓度。在患有IBD的犬中，评估犬粪便S100A12浓度与临床疾病活动度（使用犬慢性肠病临床活动指数评分系统）以及内镜和组织学疾病严重程度（使用半定量分级系统）之间的相关性。患有IBD的犬粪便犬S100A12浓度（中位数[四分位间距]：223[21 - 3477]ng/g）显著高于健康对照犬（中位数[四分位间距]：9[5 - 31]ng/g；P<0.0001）。犬粪便S100A12浓度与犬慢性肠病临床活动指数（CCECAI）评分（ρ=0.4778；P=0.0408）以及十二指肠（ρ=0.4703；P=0.0354）和结肠（ρ=0.9747；P=0.0144）内镜病变的严重程度相关，但与组织病理学变化的严重程度无关，除了结肠的炎症病变（ρ=0.8669；P=0.0230）。粪便犬S100A12浓度≥273ng/g粪便可区分：（a）任何胃肠道部位有中度至重度内镜疾病的犬与内镜疾病至多为轻度的犬；（b）临床疾病非常严重（即CCECAI评分≥12）的犬与CCECAI评分<12的犬，敏感性分别为71%和90%，特异性分别为89%和75%。本研究表明，患有IBD的犬粪便犬S100A12浓度升高。此外，本研究表明，犬粪便S100A12与患有IBD的犬的临床疾病活动度、内镜病变严重程度以及结肠炎症严重程度相关。粪便S100A12浓度可能作为患有IBD的犬炎症的生物标志物具有实用价值。
